AtheroNova has entered into an agreement with Frontage Laboratories to commence work on the formulation, compounding and tabletization of the AHRO-001 tablets.
Frontage will commence work on the analysis, formulation and validation of the various processes and procedures for manufacturing AHRO-001 in advance of the upcoming Phase I human clinical studies.
AtheroNova CEO Thomas Gardner said, "We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months."
Frontage CEO Song Li said, "Frontage's 10-year history of delivering pharmaceutical R&D services in a fast and efficient manner means the millions of patients suffering from atherosclerosis are that much closer to a potential cure."
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis.
